ABTC-0904: targeting glioma stem cells in GBM: a phase 0/II study of hedgehog pathway inhibitor GDC-0449.

Andrew E SloanCharles J NockXiaobu YeRobert BuerkiSusan ChangGlenn LesserAndrew NordenTimothy CloughesyJeffrey OlsonAmber Kerstetter-FogleJeremy RichJoy FisherSerena DesideriNaoko TakebeWilliam TimmerStuart GrossmanMichael Prados

Published in: Journal of neuro-oncology (2022)

neurosphere formation, but had little clinical efficacy as a single agent in rGBM. This suggests growth and maintenance of rGBM is not solely dependent on the SHH pathway thus targeting SMO may require combined approaches.

Keyphrases

phase ii study
stem cells
cancer therapy
open label
locally advanced
randomized controlled trial
clinical trial
drug delivery
bone marrow
rectal cancer
mesenchymal stem cells
study protocol